These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 681745)

  • 1. The C5b-6 complex: reaction with C7, C8, C9.
    Podack ER; Biesecker G; Kolb WP; Müller-Eberhard HJ
    J Immunol; 1978 Aug; 121(2):484-90. PubMed ID: 681745
    [No Abstract]   [Full Text] [Related]  

  • 2. Reaction of partial identity between the C56-9 complex derived from target membranes and from inulin-activated serum.
    Bhakdi S; Bhakdi-Lehnen B; Ey P; Bjerrum OJ
    Monogr Allergy; 1977; 12():56-61. PubMed ID: 411027
    [No Abstract]   [Full Text] [Related]  

  • 3. The C5b-9 complex: subunit composition of the classical and alternative pathway-generated complex.
    Podack ER; Kolb WP; Muller-Eberhard HJ
    J Immunol; 1976 May; 116(5):1431-4. PubMed ID: 1270802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8 beta, and the b domain of C9.
    Tschopp J; Chonn A; Hertig S; French LE
    J Immunol; 1993 Aug; 151(4):2159-65. PubMed ID: 8345200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The terminal membrane C5b-9 complex of human complement. Evidence for the existence of multiple protease-resistant polypeptides that form the trans-membrane complement channel.
    Bhakdi S; Tranum-Jensen J; Klump O
    J Immunol; 1980 May; 124(5):2451-7. PubMed ID: 6154104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement lysis of human erythrocytes. II. A unique interaction of human C8 and C9 with paroxysmal nocturnal hemoglobinuria erythrocytes.
    Packman CH; Rosenfeld SI; Jenkins DE; Leddy JP
    J Immunol; 1980 Jun; 124(6):2818-23. PubMed ID: 7189536
    [No Abstract]   [Full Text] [Related]  

  • 7. [Immunoenzyme determination of the C5b-9 complex of the complement system].
    Rus H; Niculescu F; Cristea A; Vlaicu R
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Bacteriol Virusol Parazitol Epidemiol; 1986; 31(1):35-40. PubMed ID: 3738363
    [No Abstract]   [Full Text] [Related]  

  • 8. Proteolysis of the monomeric and dimeric C5b-9 complexes of complement: alteration in the susceptibility to proteases of the C9 subunits associated with C5b-9 dimerization.
    Yamamoto K; Migita S
    J Immunol; 1981 Aug; 127(2):423-6. PubMed ID: 7019323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deviated lysis: transfer of complement lytic activity to unsensitized cells. I. Generation of the transferable activity on the surface of complement resistant bacteria.
    Rother U; Hänsch G; Menzel J; Rother K
    Z Immunitatsforsch Exp Klin Immunol; 1974 Nov; 148(2):172-86. PubMed ID: 4283273
    [No Abstract]   [Full Text] [Related]  

  • 10. The structural events associated with the attachment of complement components to cell membranes in reactive lysis.
    Dourmashkin RR
    Immunology; 1978 Aug; 35(2):205-12. PubMed ID: 750370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of the fifth and sixth component of the complement system: similarities between C5b6 and C(56)a with respect to lytic enhancement by cell-bound C3b or A2C, and species preferences of target cell.
    Hänsch GM; Hammer CH; Mayer MM; Shin ML
    J Immunol; 1981 Sep; 127(3):999-1002. PubMed ID: 6911149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic action and other metabolic consequences of terminal complement proteins.
    Shin ML; Carney DF
    Prog Allergy; 1988; 40():44-81. PubMed ID: 3281171
    [No Abstract]   [Full Text] [Related]  

  • 13. Determination of the number of lytic sites in biconcave and spheroid erythrocyte ghosts after complement lysis.
    Bauer J; Podack ER; Valet G
    J Immunol; 1979 May; 122(5):2032-6. PubMed ID: 448115
    [No Abstract]   [Full Text] [Related]  

  • 14. Incorporation of human complement C8 into the membrane attack complex is mediated by a binding site located within the C8beta MACPF domain.
    Brannen CL; Sodetz JM
    Mol Immunol; 2007 Feb; 44(5):960-5. PubMed ID: 16624411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum lipoproteins and C567-INH activity.
    Lint TF; Behrends CL; Gewurz H
    J Immunol; 1977 Sep; 119(3):883-8. PubMed ID: 561124
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunologically mediated membrane damage: the mechanism of complement action and the similarity of lymphocyte-mediated cytotoxicity.
    Mayer MM; Hammer CH; Michaels DW; Shin ML
    Transplant Proc; 1978 Dec; 10(4):707-14. PubMed ID: 366830
    [No Abstract]   [Full Text] [Related]  

  • 17. The membrane attack mechanism of complement: photolabeling reveals insertion of terminal proteins into target membrane.
    Hu VW; Esser AF; Podack ER; Wisnieski BJ
    J Immunol; 1981 Jul; 127(1):380-6. PubMed ID: 7240749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence that C5b recognizes and mediates C8 incorporation into the cytolytic complex of complement.
    Stewart JL; Kolb WP; Sodetz JM
    J Immunol; 1987 Sep; 139(6):1960-4. PubMed ID: 3624872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunologic tests: C6, C7, C8 and C9].
    Hatanaka M; Shimizu A
    Nihon Rinsho; 2005 Jul; 63 Suppl 7():92-4. PubMed ID: 16111197
    [No Abstract]   [Full Text] [Related]  

  • 20. Complement component C7 is a plasminogen-binding protein.
    Reinartz J; Hänsch GM; Kramer MD
    J Immunol; 1995 Jan; 154(2):844-50. PubMed ID: 7814888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.